Aquestive therapeutics strengthens board of directors with appointments of julie krop, m.d., and marco taglietti, m.d.

Warren, n.j., feb. 09, 2021 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, today announced the appointment of julie krop, m.d., chief medical officer of freeline therapeutics (nasdaq: frln), and marco taglietti, m.d., director, president and chief executive officer of scynexis (nasdaq: scyx), to the board of directors of the company effective february 10, 2021. aquestive also announced the resignation of douglas k. bratton from the board of directors after more than 17 years of service. aquestive's board of directors will now be comprised of eight directors, seven of whom are independent. dr. krop will serve as a member of the board's nominating and corporate governance committee and dr. taglietti will serve as a member of the board's audit committee.
AQST Ratings Summary
Quant
AQST Quant Ranking
Sector
Industry
Quant Rating
Quant Score